GAIN Study
Study Sponsor: Cortexyme

Do You or Someone You Love Have Alzheimer’s Disease?

Consider Participating in the GAIN Trial

GAIN is a clinical trial evaluating whether an investigational oral drug is safe and can halt the progression of Alzheimer’s disease by reducing the damage caused by bacteria in the brain. Eligible study participants are being recruited at study sites around the country.

A Revolutionary New Approach to Understanding Alzheimer’s

The GAIN Trial is based on the growing body of scientific evidence that the bacteria P. gingivalis, commonly associated with gum disease, can infect the brain and cause Alzheimer’s disease. COR388 is an investigational drug designed to inactivate toxic proteins released by the bacteria and stop or slow further damage to healthy brain cells. A study of COR388 in a small group of Alzheimer’s patients has shown promise in improving memory.

You or a loved one may be eligible for the study if you:

  • Are 55 to 80 years old
  • Have been diagnosed with mild to moderate Alzheimer’s disease 
  • Have a caregiver or family member who will attend study visits, report on daily activities and oversee you taking medication